CN111100163A — 一种马拉硫磷原药及其制备方法
Assigned to Jiangsu Tenglong Biological Pharmaceutical Co Ltd · Expires 2020-05-05 · 6y expired
What this patent protects
本发明一种马拉硫磷原药,原药按质量百分比包括以下几种组分:顺丁烯二酸:20‑26%,乙醇:12‑18%,催化剂:3‑5%,甲基硫化物:1‑4%,助剂:2.6‑3.8%,溶剂:4‑8%,稳定剂:1‑4%,光稳定剂:3.6‑4.8%,悬浮剂:0.2‑0.5%,余量为去离子水,本发明有效的提升了马拉硫磷稳定性,便于储存和运输,含硫磷废水量减少80%,有效控降环保处理成本,减少环境影响,减轻环保压力。
USPTO Abstract
本发明一种马拉硫磷原药,原药按质量百分比包括以下几种组分:顺丁烯二酸:20‑26%,乙醇:12‑18%,催化剂:3‑5%,甲基硫化物:1‑4%,助剂:2.6‑3.8%,溶剂:4‑8%,稳定剂:1‑4%,光稳定剂:3.6‑4.8%,悬浮剂:0.2‑0.5%,余量为去离子水,本发明有效的提升了马拉硫磷稳定性,便于储存和运输,含硫磷废水量减少80%,有效控降环保处理成本,减少环境影响,减轻环保压力。
Drugs covered by this patent
- Ovide (MALATHION) · Taro
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.